Skip to Content
  • Previous Rank523
  • Revenues ($M)$5,872.20
  • Revenue Percent Change20.8%
  • Profits ($M)$1,198.50
  • Profits Percent Change33.8%
  • Assets ($M)$8,764.30
  • Employees6,200
  • Market Value — as of March 29, 2018 ($M)$37,086.50

The biopharmaceutical company develops and manufactures medicines concerning a range of illnesses, including asthma, pain, cancer, and infectious diseases.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

Leonard S. Schleifer
CEO Title
President, Chief Executive Officer & Director
Health Care
HQ Location
Tarrytown, N.Y.
Years on Fortune 500 List1

Regeneron Pharmaceuticals Rank History

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$5,872.2020.8%
Profits ($M)$1,198.5033.8%
Assets ($M)$8,764.30-
Total Stockholder Equity ($M)$6,144.10-
Market Value — as of March 29, 2018 ($M)$37,086.50-

Profit Ratios

Profit as % of Revenues20.4%
Profits as % of Assets13.7%
Profits as % of Stockholder Equity19.5%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)10.34
EPS % Change (from 2016)34.3%
EPS % Change (5 year annual rate)8.9%
EPS % Change (10 year annual rate)-

Total Return

Total Return to Investors (2017)2.4%
Total Return to Investors (5 year, annualized)17.1%
Total Return to Investors (10 year, annualized)31.6%